Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune DisordersRead More
Selexis provides equal employment opportunities to all employees and applicants without regard to race, color, religion, sex, national origin, disability status, or any other characteristic that is protected by law. Selexis provides a barrier-free workplace and embraces all qualified applicants with varied perspectives and backgrounds.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.